Overview

Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases

Status:
Unknown status

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to investigate the following schedules for efficacy with regard to response rate in neoadjuvant treatment of patients with non-resectable liver metastases: - Cetuximab/FOLFOXIRI and cetuximab/FOLFIRI in patients with ras wild type tumours and - Bevacizumab/FOLFOXIRI and FOLFOXIRI in patients with ras mutant tumours.

Phase:

Phase 2

Details

Lead Sponsor:

Technische Universität Dresden

Treatments:

Bevacizumab
Camptothecin
Cetuximab
Fluorouracil
Folic Acid
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin